Sign inJoin
Company / Finance

CRISPR Therapeutics AG

CRSP · NASDAQ

A Coverage Bootstrap CRISPR Therapeutics company evaluation covering CASGEVY, in-vivo editing, pipeline optionality, cash runway, commercialization, clinical risk, dilution, and valuation framework.

FollowAdd to WatchlistAsk Question
Coverage BootstrapDeep DiveBiotechGene EditingHigh RiskFive-Year Double Thesis
Latest ReportMay 8, 2026CRISPR Therapeutics: commercial gene editing meets binary pipeline riskView report ->Total Reports2Published reportsView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->
Company filters2 of 2 reports match
Clear filters
Selected tags
BiotechGene Editing
Clear tags
MatchAny tagAll tags
Latest Thesis

CRISPR Therapeutics: commercial gene editing meets binary pipeline risk

A Coverage Bootstrap CRISPR Therapeutics company evaluation covering CASGEVY, in-vivo editing, pipeline optionality, cash runway, commercialization, clinical risk, dilution, and valuation framework.

May 8, 2026Research reportSlides available
Read reportOpen slidesDiscussion (0)
CRISPR Therapeutics AGTherapeutics: commercial gene editing meets binary pipeline riskMay 8, 2026
Member workspace

Financials and workspace tools are for paid members.

Paid login unlocks company financials, filing timeline, peer comparison, scorecard, and discussion. Valuation remains admin-only while we finalize market-data licensing.

Sign in to continue

Recent Reports

Compact report index for this company.

View all 2 reports ->
ReportTypeUpdatedReadActions
CRISPR Therapeutics: commercial gene editing meets binary pipeline riskA Coverage Bootstrap CRISPR Therapeutics company evaluation covering CASGEVY, in-vivo editing, pipeline optionality, cash runway, commercialization, clinical risk, dilution, and valuation framework.Coverage BootstrapMay 8, 2026Research reportReadSlides
CRISPR Therapeutics: CASGEVY launch, pipeline proof, and binary riskA CRISPR Therapeutics five-year double thesis focused on CASGEVY commercialization, cash runway, in-vivo pipeline proof, clinical risk, and dilution discipline.BiotechMay 8, 2026Research reportReadSlides